Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 562

Similar articles for PubMed (Select 19299111)

1.

Hyperammonemia following intravenous valproate loading.

DeWolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi NA.

Epilepsy Res. 2009 Jul;85(1):65-71. doi: 10.1016/j.eplepsyres.2009.02.012. Epub 2009 Mar 18.

PMID:
19299111
2.

Safety of rapid intravenous loading of valproate.

Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E.

Epilepsia. 2007 Mar;48(3):478-83. Epub 2007 Feb 22.

PMID:
17319914
3.

The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.

Hamed SA, Abdella MM.

Epilepsy Res. 2009 Sep;86(1):32-41. doi: 10.1016/j.eplepsyres.2009.04.002. Epub 2009 May 14.

PMID:
19446440
4.

Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?

Kondo T, Ishida M, Kaneko S, Hirano T, Otani K, Fukushima Y, Muranaka H, Koide N, Yokoyama M, Nakata S, et al.

Epilepsia. 1992 May-Jun;33(3):550-4.

PMID:
1350534
5.

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.

Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, Chang CC, Chang WN, Chuang YC.

Medicine (Baltimore). 2014 Sep;93(11):e66. doi: 10.1097/MD.0000000000000066.

PMID:
25192484
6.

[Hyperammonemia in valproate therapy in children and adolescents].

Laub MC.

Nervenarzt. 1986 May;57(5):314-8. German.

PMID:
3088461
7.
8.

Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.

Gidal BE, Inglese CM, Meyer JF, Pitterle ME, Antonopolous J, Rust RS.

Pediatr Neurol. 1997 May;16(4):301-5.

PMID:
9258962
9.

[Sodium valproate: a hyperammonemic drug. Study in the epileptic and healthy volunteer].

Marescaux C, Warter JM, Laroye M, Rumbach L, Micheletti G, Koehl C, Imler M, Kurtz D.

J Neurol Sci. 1983 Feb;58(2):195-209. French.

PMID:
6403673
10.

Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.

Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K, Kagawa Y, Inoue Y.

Epilepsy Res. 2012 Sep;101(3):202-9. doi: 10.1016/j.eplepsyres.2012.04.001. Epub 2012 Apr 28.

PMID:
22542569
11.

Blood ammonia level during valproic acid therapy.

Kugoh T, Yamamoto M, Hosokawa K.

Jpn J Psychiatry Neurol. 1986 Dec;40(4):663-8.

PMID:
3110472
12.

Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.

Vossler DG, Wilensky AJ, Cawthon DF, Kraemer DL, Ojemann LM, Caylor LM, Morgan JD.

Epilepsia. 2002 Feb;43(2):154-9.

PMID:
11903461
13.

Risk factors for hyperammonemia in pediatric patients with epilepsy.

Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, Itoh K, Kagawa Y, Inoue Y.

Epilepsia. 2013 Jun;54(6):983-9. doi: 10.1111/epi.12125. Epub 2013 Feb 14.

PMID:
23409971
14.

Valproic acid-induced hyperammonemia: a case report.

McCall M, Bourgeois JA.

J Clin Psychopharmacol. 2004 Oct;24(5):521-6.

PMID:
15349008
15.
16.

Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.

Zaret BS, Beckner RR, Marini AM, Wagle W, Passarelli C.

Neurology. 1982 Feb;32(2):206-8.

PMID:
6798491
17.

Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.

Yagi M, Nakamura T, Okizuka Y, Oyazato Y, Kawasaki Y, Tsuneishi S, Sakaeda T, Matsuo M, Okumura K, Okamura N.

Pediatr Int. 2010 Oct;52(5):744-8. doi: 10.1111/j.1442-200X.2010.03157.x.

PMID:
20456087
18.
19.
20.

Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures.

Yu KT, Mills S, Thompson N, Cunanan C.

Epilepsia. 2003 May;44(5):724-6.

PMID:
12752474
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk